Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Logos for Enara Bio and Boehringer Ingelheim

Enara Bio has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over  €876M (£787M), to research and develop novel targeted cancer immunotherapies.

The partnership will provide additional funding to advance Dark Antigen research, further independent validation of Enara’s novel EDAPT™ platform, and brings a wealth of big pharma development resources to help drive discoveries into the clinic.

Key features of the deal include:

  • Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio’s EDAPT™ platform and Dark Antigen™ discovery work and supports the ongoing cell therapy based therapeutic approach
  • Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers
  • Enara Bio will receive an upfront payment, together with research/preclinical milestones and licensing fees for each tumour type explored
  • Enara Bio is eligible to receive more than €876M in clinical, regulatory and commercial milestones, in addition to royalties on future product sales
  • Partnership strengthens Boehringer Ingelheim’s position in the cancer vaccine and T‐cell engager spaces

 

‘We’re excited to be partnered with an innovation-led company that has built considerable expertise in cancer vaccines and immune-oncology.’

Kevin Pojasek, CEO Enara Bio.

To read the full story click here

Enara Bio

Enara Bio is an SV Health backed start-up, originally named Ervaxx, that was founded in 2016 using technology developed at the Francis Crick Institute, London.

The company joined the BioEscalator in 2018 with 5 employees and through connections including, immunopeptidomics expert Dr Nicola Ternette of University of Oxford and Dr Adrian Hill of University of Oxford and Vaccitech, has developed 2 proprietary platforms and grown the team to over 20. Enara is currently in the process of expanding operations and relocating to The Oxford Science Park.

Boehringer Ingelheim

Boehringer Ingelheim is a family owned pharmaceutical company based in Ingelheim, Germany. It is the world’s largest privately held pharmaceutical company which focuses on innovation to benefit both human and animal health.